HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Mci-186

HCID 4021
New reaction
Print
Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
89-25-8
Standard SMILES
CC1=NN(c2ccccc2)C(=O)C1
InChIKey
QELUYTUMUWHWMC-UHFFFAOYSA-N
Molecular formula
C10H10N2O
Average molar mass
174.2 g/mol
Monoisotopic mass
174.07931295

Overview

1-phenyl-3-methyl-5-pyrazolone appears as white to off-white powder or crystals. (NTP, 1992)

Names & identifiers

Preferred name
Mci-186
IUPAC
5-methyl-2-phenyl-4H-pyrazol-3-one
English name
5-Methyl-2-phenyl-1,2-dihydropyrazol-3-one
Molecular formula
C10H10N2O
Molecular weight
174.2

Names & synonyms

MCI-186MCI 186RefChem:57584edaravone89-25-83-METHYL-1-PHENYL-2-PYRAZOLIN-5-ONENorphenazoneRadicut1-Phenyl-3-methyl-5-pyrazoloneDeveloper ZMethylphenylpyrazoloneNorantipyrine
Show more names
PMPMONOPYRAZOLONEPHENYLMETHYLPYRAZOLON
PhenylmethylpyrazoloneC.I. Developer 1RadicavaPhenyl methyl pyrazolone3-Methyl-1-phenyl-1H-pyrazol-5(4H)-one3-Methyl-1-phenyl-5-pyrazolone5-Methyl-2-phenyl-2,4-dihydro-3H-pyrazol-3-one5-methyl-2-phenyl-4H-pyrazol-3-one

Database identifiers

CAS
89-25-8
PubChem CID
4021
DTXSID
DTXSID9021130
ChEMBL
CHEMBL290916
ChEBI
CHEBI:31530
UNII
S798V6YJRP
EC Number
201-891-0
Nikkaji
J37.341I

Properties

Computed structural properties

XLogP
1.3
Topological polar surface area
32.7 Ų
Hydrogen bond donors
0
Hydrogen bond acceptors
2
Rotatable bonds
1
Heavy atoms
13
Formal charge
0
Complexity
241

Experimental & physicochemical properties

Chemical ClassesNitrogen Compounds -> Pyrazoles
DrugsPharmaceuticals -> Listed in ZINC15
Cosmetics · 2 items

Cosmetic ingredients (Phenyl Methyl Pyrazolone) -> CIR (Cosmetic Ingredient Review)

Hair dyeing

LogP1.44
Color/Form · 2 items

MONOCLINIC PRISMS FROM WATER

WHITE POWDER OR CRYSTALS

Solubility · 3 items

less than 1 mg/mL at 73 °F (NTP, 1992)

SOL IN HOT WATER & HOT ALCOHOL; SLIGHTLY SOL IN BENZENE; INSOL IN PETROLEUM ETHER

25.4 [ug/mL] (The mean of the results at pH 7.4)

Human Drugs · 2 items

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Boiling Point · 2 items

549 °F at 105 mmHg (NTP, 1992)

191 °C @ 17 MM HG; 287 °C @ 105 MM HG

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS Classification · 6 items

This chemical does not meet GHS hazard criteria for 7.7% (16 of 209) of reports.

Warning

H302 (26.8%): Harmful if swallowed [Warning Acute toxicity, oral]

P261, P264, P264+P265, P270, P271, P272, P273, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P319, P321, P330, P332+P317, P333+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 209 reports by companies from 25 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Warning

Hazard information

Regulatory Information · 3 items

Chemical: 3H-Pyrazol-3-one, 2,4-dihydro-5-methyl-2-phenyl-

REACH registered substance: 3-methyl-1-phenyl-5-pyrazolone (EC: 201-891-0)

3H-Pyrazol-3-one, 2,4-dihydro-5-methyl-2-phenyl-: Does not have an individual approval but may be used under an appropriate group standard

Other Safety InformationIMAP assessments - 3H-Pyrazol-3-one, 2,4-dihydro-5-methyl-2-phenyl-: Human health tier II assessment
Fire HazardsFlash point data for this chemical are not available. It is probably combustible. (NTP, 1992)
Health HazardsSYMPTOMS: Symptoms of exposure to this compound may include irritation of the skin, eyes and mucous membranes.
Hazards Summary · 1 item

Emergency treatment: Irritants; [HSDB] A skin, eye, and mucous membrane irritant; [CAMEO] Causes no to mild skin and eye irritation in rabbits; Not sensitizing to guinea pig skin; [IUCLID] No teratogenicity observed in experimental animals, but reduced birth weight and fetal loss seen at high doses; [REPROTOX] No evidence for carcinogenicity in mice or rats; [NTP] A mild eye irritant; Causes changes in liver and spleen in intravenous studies of dogs; [RTECS]

Chemistry & industry

Pharmacology

ATC Code · 2 items

N - Nervous system

QN - Nervous system

Protein BindingEdaravone is 92% bound to human serum proteins, mainly to albumin, with no concentration dependence in the range of 0.1 to 50 micromol/L.
PharmacodynamicsEdaravone works to delay the disease progression of neurological disorders such as ischemic stroke and ALS by limiting the extent of neuronal damage or death.
Mechanism of Action · 1 item

Oxidative stress and reactive oxygen species (ROS) production have been implicated in various neurological disorders, such as amyotrophic lateral sclerosis (ALS) and cerebral ischemia. Oxidative stress caused by excess ROS damages endothelial cells in the cerebral vasculature as well as neuronal cell membranes, leading to neuronal cell death. Edaravone is a free radical scavenger that scavenges and suppresses the generation of hydroxyl radicals and peroxynitrite radicals. The exact mechanism of action of edaravone in ALS has not been fully elucidated; however, edaravone is thought to mediate therapeutic effects via its antioxidant properties. Since oxidative stress has been implicated in the pathophysiology of ALS and cerebral ischemia, inhibiting lipid peroxidation, suppressing endothelial cell damage induced by lipid peroxides, and scavenging free radicals may lead to neuroprotective effects. Edaravone has no effect on superoxide production. It is suggested that edaravone may also possess anti-inflammatory properties, as it inhibited neutrophil activation and suppressed inducible nitric oxide synthase (iNOS) and neuronal nitric oxide synthase (nNOS) expression in animal models. It was also shown to ameliorate ROS-induced inflammatory oxidative stress after ischemic brain reperfusion.

Biological Half-LifeThe mean terminal elimination half-life of edaravone is approximately 4.5 to nine hours. The half-lives of its metabolites range from three to six hours.
Metabolism/Metabolites · 1 item

The metabolites of edaravone have not been fully characterized. Edaravone is metabolized to a sulfate conjugate and a glucuronide conjugate, which are not pharmacologically active. The glucuronide conjugation of edaravone involves multiple uridine diphosphate glucuronosyltransferase (UGT) isoforms (UGT1A1, UGT1A6, UGT1A7, UGT1A8, UGT1A9, UGT1A10, UGT2B7, and UGT2B17). In human plasma, edaravone is mainly detected as the sulfate conjugate, which is presumed to be formed by sulfotransferases. Oral edaravone results in 1.3- and 1.7-fold higher exposures for both sulfate and glucuronide metabolites, respectively, when compared to intravenously-administered edaravone because of first-pass metabolism.

Related reactions

21 records
New reaction record
HRID 105365 reaction equation
HRID 105365As reactant
HRID 293402 reaction equation
HRID 293402As reactant
HRID 302741 reaction equation
HRID 302741As reactant
HRID 315839 reaction equation
HRID 315839As reactant
HRID 362451 reaction equation
HRID 362451As reactant
HRID 382796 reaction equation
HRID 382796As reactant
HRID 531189 reaction equation
HRID 531189As reactant
HRID 950576 reaction equation
HRID 950576As reactant
PreviousPage 1 of 3

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Melting Point · 3 items

261 to 266 °F (NTP, 1992)

127 °C

128.9 °C

Vapor Pressure · 2 items

less than 0.01 mmHg at 68 °F (NTP, 1992)

LESS THAN 0.01 MM @ 20 °C

Refractive IndexMAX ABSORPTION (ALCOHOL): 280 NM SHOULDER (LOG E= 3.6) INDEX OF REFRACTION: 1.637; MAX ABSORPTION (ALCOHOL): 245 NM (LOG E= 1.1)
Physical Description · 2 items

1-phenyl-3-methyl-5-pyrazolone appears as white to off-white powder or crystals. (NTP, 1992)

White solid; [Merck Index] Light yellow odorless powder; [Alfa Aesar MSDS]

Physicochemical properties

Melting point
126 · 126-128 °C(lit.)
Boiling point
287 °C265 · 287 °C265 mm Hg(lit.)
Density
1 · 1,12 g/cm3
vapor pressure
0.016 Pa · 0.016Pa at 20℃
refractive index
1.63 · 1.6300 (estimate)
Flash point
191 °C/17mm · 191°C/17mm
storage temp.
2 · 2-8°C
solubility
3.3 g/l · 3.30g/l
pka
2.73 · 2.73±0.50(Predicted)
form
Crystalline Powder
color
Yellow to beige
PH
4 · 4.0-4.4 (H2O, 20℃)(saturated aqueous solution)
Water Solubility
3 g/L · 3 g/L (20 ºC)
Merck
14 · 14,6713
BRN
609575 · 609575
Stability
2 years · Stable for 2 years from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20° for up to 3 months.
Major Application
peptide synthesis
Cosmetics Ingredients Functions
HAIR DYEING
InChI
1S/C10H10N2O/c1-8-7-10(13)12(11-8)9-5-3-2-4-6-9/h2-6H,7H2,1H3
InChIKey
QELUYTUMUWHWMC-UHFFFAOYSA-N
SMILES
CC1=NN(C(=O)C1)c2ccccc2
LogP
0.75 at · 0.75 at 24℃
Toxicology and Carcinogenesis
1 · Bioassay of 1-Phenyl-3-methyl-5-pyrazolone for Possible Carcinogenicity (CASRN 89-25-8)
CAS DataBase Reference
89 · 89-25-8(CAS DataBase Reference)
FDA UNII
798 V6YJRP · S798V6YJRP
ATC code
7 XX14 · N07XX14
NIST Chemistry Reference
3 H-Pyrazol-3-one, · 3H-Pyrazol-3-one, 2,4-dihydro-5-methyl-2-phenyl-(89-25-8)
EPA Substance Registry System
1 · 1-Phenyl-3-methyl-5-pyrazolone (89-25-8)
UNSPSC Code
41116107 · 41116107
NACRES
77 · NA.77
Symbol(GHS)
7 · GHS07
Signal word
Warning
Hazard statements
302 · H302-H319
Precautionary statements
264 · P264-P270-P280-P301+P312-P305+P351+P338-P337+P313
PPE
95 · dust mask type N95 (US), Eyeshields, Gloves
Hazard Codes
Xi
Risk Statements
36 · 36/37/38
Safety Statements
26 · 26-36
WGK Germany
1 · 1
RTECS
9625000 · UQ9625000
TSCA
TSCA listed
HS Code
2933199090 · 2933199090
Storage Class
11 · 11 - Combustible Solids
Hazard Classifications
4 OralEye · Acute Tox. 4 OralEye Irrit. 2
Hazardous Substances Data
89 · 89-25-8(Hazardous Substances Data)
Toxicity
50 orl-rat: · LD50 orl-rat: 3500 mg/kg LONZA# 08FEB79
REACH Registrations
Active
Reactive GroupAmides and Imides
Special ReportsDHEW/NCI; Bioassay of 1-Phenyl-3-methyl-5-pyrazolone for Possible Carcinogenicity (1978) Technical Rpt Series No. 141 DHEW Pub No. (NIH) 78-1396
Reactivity Profile · 1 item

Amines are chemical bases. They neutralize acids to form salts plus water. These acid-base reactions are exothermic. The amount of heat that is evolved per mole of amine in a neutralization is largely independent of the strength of the amine as a base. Amines may be incompatible with isocyanates, halogenated organics, peroxides, phenols (acidic), epoxides, anhydrides, and acid halides. Flammable gaseous hydrogen is generated by amines in combination with strong reducing agents, such as hydrides.

Air and Water ReactionsInsoluble in water.
Hazard Classes and Categories · 2 items

Acute Tox. 4 (26.8%)

Skin sensitisation - category 1

Safety & protection

Fire FightingFires involving this material can be controlled with a dry chemical, carbon dioxide or Halon extinguisher. (NTP, 1992)
First Aid · 1 item

EYES: First check the victim for contact lenses and remove if present. Flush victim's eyes with water or normal saline solution for 20 to 30 minutes while simultaneously calling a hospital or poison control center. Do not put any ointments, oils, or medication in the victim's eyes without specific instructions from a physician. IMMEDIATELY transport the victim after flushing eyes to a hospital even if no symptoms (such as redness or irritation) develop.

Nonfire Spill Response · 1 item

SMALL SPILLS AND LEAKAGE: Should a spill occur while you are handling this chemical, FIRST REMOVE ALL SOURCES OF IGNITION, then you should dampen the solid spill material with ethanol and transfer the dampened material to a suitable container. Use absorbent paper dampened with ethanol to pick up any remaining material. Seal the absorbent paper, and any of your clothes, which may be contaminated, in a vapor-tight plastic bag for eventual disposal. Solvent wash all contaminated surfaces with ethanol followed by washing with a soap and water solution. Do not reenter the contaminated area until the Safety Officer (or other responsible person) has verified that the area has been properly cleaned.

Protective Action Criteria (PAC) · 3 items

5.7 [mg/m3]

63 [mg/m3]

380 [mg/m3]

Personal Protective Equipment (PPE) · 1 item

RECOMMENDED RESPIRATOR: Where the neat test chemical is weighed and diluted, wear a NIOSH-approved half face respirator equipped with an organic vapor/acid gas cartridge (specific for organic vapors, HCl, acid gas and SO2) with a dust/mist filter. (NTP, 1992)

Toxicology

Hepatotoxicity · 1 item

Serum aminotransferase elevations occur in a small proportion of patients on edaravone therapy, but the frequency, timing of onset, duration and severity of these elevations has not been defined. The rates of abnormal liver tests during edaravone therapy were said to be similar to those during placebo treatment. Most elevations resolved spontaneously, and there were no reports of drug discontinuation for serum enzyme elevations. Clinically apparent liver injury due to edaravone was not reported in the prelicensure trials and has not been reported with subsequent clinical use of edaravone, but the numbers of patients treated have been few. Thus, clinically apparent liver injury from edaravone must be rare if it occurs at all.

Toxicity SummarySafe in the present practices of use and concentration. Ingredient, concentration, and use information are available in documents discoverable at https://cir-reports.cir-safety.org
Ongoing Test Status · 1 item

The following link will take the user to the National Toxicology Program (NTP) Test Agent Search Results page, which tabulates all of the "Standard Toxicology & Carcinogenesis Studies", "Developmental Studies", and "Genetic Toxicity Studies" performed with this chemical. Clicking on the "Testing Status" link will take the user to the status (i.e., in review, in progress, in preparation, on test, completed, etc.) and results of all the studies that the NTP has done on this chemical. [http://ntp-apps.niehs.nih.gov/ntp_tox/index.cfm?fuseaction=ntpsearch.searchresults&searchterm=89-25-8]

Carcinogen Classification · 6 items

1-Phenyl-3-methyl-5-pyrazolone

TR-141: Bioassay of 1-Phenyl-3-methyl-5-pyrazolone for Possible Carcinogenicity (CASRN 89-25-8) (1978 )

06/29/78

No Evidence

No Evidence

No Evidence

Drug Induced Liver Injury · 6 items

Drug Induced Liver Injury Rank (DILIrank 2.0)

Edaravone

vNo-DILI-concern

0

No match

DOI:10.1016/j.drudis.2016.02.015

Non-Human Toxicity Excerpts... Levels of Evidence of Carcinogenicity: Male Rats: Negative; Female Rats: Negative; Male Mice: Negative; Female Mice: Negative.
National Toxicology Program Studies · 1 item

A bioassay of 1-phenyl-3-methyl-5-pyrazolone for possible carcinogenicity was conducted using Fischer 344 rats and B6C3Fl mice. l-Phenyl-3-methyl-5-pyrazolone was admin in the feed, at either of two concn, to groups of 49 or 50 male and 50 female animals of each species. The high and low concn of 1-phenyl-3-methyl-5-pyrazolone utilized were, respectively, 5,000 and 2,500 ppm for rats and 15,000 and 7,500 ppm for mice. Twenty animals of each species and sex were placed on test as controls. After a 103 wk period of chemical admin, there was an additional observation period of 2 wk for rats. A 102 wk period of chemical admin was followed by an additional 2 wk observation period for mice. In both species adequate numbers of animals survived sufficiently long to be at risk from late developing tumors. ... Under the conditions of this bioassay, there was no evidence for the carcinogenicity of 1-phenyl-3-methyl-5-pyrazolone to Fischer 344 rats or B6C3Fl mice. ... Levels of Evidence of Carcinogenicity: Male Rats: Negative; Female Rats: Negative; Male Mice: Negative; Female Mice: Negative.

Safety data

PPE
dust mask type N95 (US), Eyeshields, Gloves
wgk
1
tsca
TSCA listed
rtecs
UQ9625000
hs_code
2933199090
Toxicity
LD50 orl-rat: 3500 mg/kg LONZA# 08FEB79
risk_code
36/37/38
Signal word
Warning
Symbol(GHS)
GHS07
hazard_code
Xi
safety_code
26-36
Storage Class
11 - Combustible Solids
Hazard statements
H302-H319
REACH Registrations
Active
Hazard Classifications
Acute Tox. 4 OralEye Irrit. 2
Precautionary statements
P264-P270-P280-P301+P312-P305+P351+P338-P337+P313
Hazardous Substances Data
89-25-8(Hazardous Substances Data)
MeSH Pharmacological Classification · 2 items

Substances that eliminate free radicals. Among other effects, they protect PANCREATIC ISLETS against damage by CYTOKINES and prevent myocardial and pulmonary REPERFUSION INJURY.

Drugs intended to prevent damage to the brain or spinal cord from ischemia, stroke, convulsions, or trauma. Some must be administered before the event, but others may be effective for some time after. They act by a variety of mechanisms, but often directly or indirectly minimize the damage produced by endogenous excitatory amino acids.

Absorption, Distribution and Excretion · 4 items

One study investigated the absorption of edaravone in healthy adults, who either received a single oral (105 mg/mL) or intravenous (60 mg/60 min) dose. The mean Cmax (CV%) and Tmax were 1656 (44.3) ng/mL and 0.5 hours, respectively, following oral administration. The absolute oral bioavailability is about 57% because of first-pass metabolism. The mean Cmax (CV%) and Tmax were 1253 (18.3) ng/mL and one hour, respectively, following intravenous administration. When intravenously administered, the maximum plasma concentration (Cmax) of edaravone was reached by the end of infusion. The Cmax and area under the concentration-time curve (AUC) of edaravone increases more than dose-proportional over the dose range of 30 to 300 mg. Edaravone does not accumulate in plasma with once-daily or multiple-dose administration. The Cmax and AUC decreased when the oral suspension formulation of edaravone was administered with a high-fat meal.

In Japanese and Caucasian healthy volunteer studies, edaravone was excreted mainly in the urine as its glucuronide conjugate (60-80% of the dose up to 48 hours). Approximately 6-8% of the dose was recovered in the urine as the sulfate conjugate, and <1% of the dose was recovered in the urine as the unchanged drug. _In vitro_ studies suggest that the sulfate conjugate of edaravone is hydrolyzed back to edaravone, which is then converted to the glucuronide conjugate in the kidney before excretion into the urine.

After intravenous administration, edaravone has a mean volume of distribution of 63.1 L, suggesting substantial tissue distribution. Edaravone has an apparent volume of distribution of 164 L following oral administration. Edaravone readily crosses the blood-brain barrier.

Following intravenous administration, the total clearance of edaravone is estimated to be 35.9 L/h. The apparent total clearance of edaravone is estimated to be 67.9L/h following oral administration.

Uses & manufacturing

Uses · 5 items

CIR ingredient: Phenyl Methyl Pyrazolone

Used as an intermediate for dyes and drugs, reagent to detect cyanide, and developer for diazotized direct dyes; [HSDB] Used in the treatment of strokes; [Merck Index] Used for synthesis in the chemical industry and in the textile processing industry; [IUCLID] Used in hair dyes; [ExPub: EC]

Textiles (Printing, Dyeing, or Finishing) [Category: Industry]

INTERMEDIATE FOR DYES & DRUGS; SENSITIVE REAGENT FOR DETECTION OF CYANIDE

CHEM INT FOR DYES (EG, FOR PYRAZOLONE PIGMENTS), DRUGS (EG, ANTIPYRINE & AMINOPYRINE), DEVELOPER FOR DIAZOTISED DIRECT DYES, REAGENT FOR DETECTION OF CYANIDE

U.S. Exports · 2 items

(1977) No Data

(1979) No Data

U.S. Imports · 2 items

(1977) 6.01X10+7 GRAMS (PRINCPL CUSTMS DISTS)

(1979) 1.55X10+8 GRAMS (PRINCPL CUSTMS DISTS)

U.S. Production · 2 items

(1976) 5.90X10+6 GRAMS (SALES)

(1979) PROBABLY GREATER THAN 2.27X10+6 GRAMS

Methods of Manufacturing · 2 items

CONDENSATION OF PHENYLHYDRAZINE WITH ETHYL ACETOACETATE

BY CONDENSATION OF PHENYLHYDRAZINE WITH ETHYLACETOACETATE.

Household ProductsInformation on 99 consumer products that contain Phenyl methyl pyrazolone in the following categories is provided:
Use ClassificationCosmetics -> Hair dyeing
General Manufacturing Information3H-Pyrazol-3-one, 2,4-dihydro-5-methyl-2-phenyl-: ACTIVE
Applications · 6 items

DescriptionEdaravone was marketed in Japan for improving neurologic recovery following acute brain infarction. Currently, several agents classified as neuroprotectants and acting by diverse mechanisms (inhibition of glutamate release, blockade of calcium channels, lazaroids) have been marketed for treating the outcomes of brain damage due to trauma, ischemia or cardiac arrest. Edavarone is the first antioxidant with free radical scavenging activity to be introduced for this pathology. This previously described molecule (in particular as norantipyrine, one of three metabolites of antipyrine in mammals) can be simply prepared by direct cyclization of phenylhydrazine with alkylacetoacetate. Edarevone is a lipophilic agent, readily accessible to brain tissue, that is capable of reducing edema in the brain following ischemia by blocking the arachidonic acid cascade triggering peroxidative neurodegeneration. Interestingly, this agent has been shown to quench active oxygen species in endothelial cell homogenate, as well as inhibiting in vitro lipid peroxidative disintegration of membranes, so making this compound effective during reperfusion following ischemic injury. As an additional indication, phase III trials started with edaravone for increasing the chance of recovery after subarachnoid hemorrhage.

DescriptionMCI-186 is a free radical scavenger with diverse protective effects in vivo. Most notably, it reduces damage due to ischemia-reperfusion injury in lung, liver, and brain in animal models of transplant, infection, traumatic brain injury, and stroke. MCI-186 provides these protective effects, at least in part, by reducing reactive oxygen species, inhibiting apoptosis, and blocking nonenzymatic peroxidation and lipoxygenase activity.

Uses3-Methyl-1-phenyl-2-pyrazolin-5-one used as reagent for detection of reducing carbohydrates by ESI/MALDI -MS.

Usesantioxidant, lipoxygenase inhibitor

UsesEdaravone inhibits the disease activity in rheumatoid arthritis.

General DescriptionA free radical scavenger and antioxidant that reduces post-ischemic brain injury. Inhibits iron-dependent peroxidation in rat brain homogenates (IC50 = 15 μM). Inhibits mitochondrial permeability transition pore.

Upstream & downstream products

Upstream raw materials

Acetyl keteneAMMONIUM NITRITE, 20% SOLNAcetoacetamideAmmonium hydroxideEthanolAcetoxyacetic acidAmmonium bisulfiteFormaldehydeFormic acidSodium nitriteAnilineHydrochloric acidp-ToluidineMethaneSulfuric acidSodium carbonateAmmoniaSodium metabisulfiteDimethyl sulfate

Downstream products

Acid yellow 17sodium [2,4-dihydro-4-[(2-hydroxy-5-nitrophenyl)azo]-5-methyl-2-phenyl-3H-pyrazol-3-onato(2-)][1-[(2-hydroxy-4-nitrophenyl)azo]-2-naphtholato(2-)]cobaltate(1-)Neutral Bordeaux D-BNTracid Light Yellow GDifenzoquat methylsulfateMordant Red 7Pyrazole3,5-DiphenylpyrazoleCuprate(2-), [4-[bis[4-(diethylamino)phenyl]hydroxymethyl]-5-[(4,5-dihydro-3-methyl-5-(oxo-κO)-1-phenyl-1H-pyrazol-4-yl)azo-κN1]-6-(hydroxy-κO)-1,3-benzenedisulfonato(4-)]-, disodium

Additional notes

DefinitionChEBI: A pyrazolone that is 2,4-dihydro-3H-pyrazol-3-one which is substituted at positions 2 and 5 by phenyl and methyl groups, respectively.